Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 July 2023Website:
http://www.aeonbiopharma.comNext earnings report:
09 May 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 19 Nov 2024 00:50:01 GMTDividend
Analysts recommendations
Institutional Ownership
AEON Latest News
AEON Biopharma, Inc. (AEON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
IRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Marc Forth, AEON's President and Chief Executive Officer, will present a corporate overview on Wednesday, September 11, 2024 at 1:30 PM ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.
– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product –
AEON Biopharma, Inc. (AEON) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Recently experiencing a decrease in value, AEON Biopharma, Inc. (AEON) has now shown a hammer chart pattern, suggesting that the stock has found a level of support. This, along with an increase in earnings estimate revisions, may result in a potential turnaround for the stock in the near future.
Atalaya Capital Management LP (Trades, Portfolio), a New York-based investment firm, recently made a significant acquisition in AEON Biopharma Inc. This article will delve into the details of the transaction, provide an overview of both Atalaya Capital Management LP (Trades, Portfolio) and AEON Biopharma Inc, and analyze the potential impact of this acquisition on the firm's portfolio and the traded company's stock performance.
What type of business is AEON Biopharma?
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
What sector is AEON Biopharma in?
AEON Biopharma is in the Healthcare sector
What industry is AEON Biopharma in?
AEON Biopharma is in the Biotechnology industry
What country is AEON Biopharma from?
AEON Biopharma is headquartered in United States
When did AEON Biopharma go public?
AEON Biopharma initial public offering (IPO) was on 24 July 2023
What is AEON Biopharma website?
https://www.aeonbiopharma.com
Is AEON Biopharma in the S&P 500?
No, AEON Biopharma is not included in the S&P 500 index
Is AEON Biopharma in the NASDAQ 100?
No, AEON Biopharma is not included in the NASDAQ 100 index
Is AEON Biopharma in the Dow Jones?
No, AEON Biopharma is not included in the Dow Jones index
When was AEON Biopharma the previous earnings report?
No data
When does AEON Biopharma earnings report?
The next expected earnings date for AEON Biopharma is 09 May 2025